Article: Peplin Releases Results for the 2009 Financial Year Ended June 30.(Financial report)

Article: LEO Buyout Gels for Peplin: $288M, Plus Phase III ...
BIOWORLD Today;  September 4, 2009 ;     700+ words ... ... complete the remaining Phase III trial of PEP005 (ingenol mebutate). Peplin had about $17.7 ... exceeded $40 million. Peplin recently completed the first Phase III study in actinic ... time, PEP005 was in Phase I. Peplin continued to fund ...

Article: Financings Roundup Peplin's $24M Private Placement to Fund ...
BIOWORLD Today;  August 20, 2008 ;     700+ words ... ... will be sufficient to fund Phase III trials of Peplin's lead drug, PEP005 ... on the body and head. Peplin plans to start a Phase III trial for nonhead lesions ... For lesions of the head, Peplin is conducting a Phase IIb trial and expects results ...

Article: Positive Results for Peplin's Phase IIb AK Trial.
Business Wire;  January 8, 2009 ;     700+ words ... ... extremely exciting and puts Peplin in a great position for further Phase III development ... Administration (FDA), Peplin plans to initiate a subsequent Phase III clinical trial ... Completion of enrollment in Peplin's first Phase III trial, REGION ...

Article: Positive Results for Peplin's Phase IIb AK ...
Biotech Week;  January 21, 2009 ;     700+ words ... ... completion of our Phase II program represents ... significant milestone for Peplin and takes us an ... exciting and puts Peplin in a great position for further Phase III development ... Administration (FDA), Peplin plans to initiate a subsequent Phase III clinical trial ...

Article: Peplin Completes Enrolment in its Final Phase 3 ...
Business Wire;  August 19, 2009 ;     700+ words ... ... BRISBANE, Australia -- Peplin, Inc. (ASX:PLI ... enrolment in its second Phase 3 clinical trial for the ... I trial, the first Phase 3 trial for non-head locations. Peplin will complete its Phase 3 clinical trials for ...

Article: Positive Results for Peplin's First Phase III AK ...
Biotech Week;  June 3, 2009 ;     700+ words ... ... adverse effects reported. Peplin will conduct its End-of-Phase II meeting with the FDA on June 3, 2009. Peplin was notified by the FDA of ... scheduling conflicts at the FDA. Peplin will initiate the Phase III program for patients with ...

Article: Peplin Initiates its Final Phase 3 Clinical Trial ...
Business Wire;  July 23, 2009 ;     700+ words ... ... BRISBANE, Queensland -- Peplin, Inc. (ASX:PLI ... its second non-head Phase 3 clinical trial to ... I trial, the first Phase 3 for non-head locations, earlier this year. Peplin will complete their Phase 3 clinical trials for ...